Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBRA: KRd versus VRd in newly diagnosed multiple myeloma
2024-518473-34-00Phase 3Authorised
- Sponsor
- Polish Myeloma Consortium
- Start
- Nov 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of carfilzomib, bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Polish Myeloma Consortium. Primary endpoints: MRD-negative complete response status at 12 months and Progression-free survival. Planned start Nov 2019; status: authorised.
02
Drugs
carfilzomibbortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-518473-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518473-34-00.